A recent systematic review assessing GLP-1 receptor agonists in AD found that, while these agents do not appear to significantly improve cognitive function via effects on amyloid-β and tau biomarkers, they may still offer metabolic and neuroprotective benefits [64]. The gene discussed is GLP1R; the disease is Alzheimer disease.